KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) Stock

HealthcareMedical Instruments & Supplies Website

Company insiders reported 0 open-market buys and 31 sales on SEC Form 4 in the 90 days to Oct 21, 2026.

Are KESTRA MEDICAL TECHNOLOGIES, LTD. insiders buying or selling?

SEC Form 4 filings
90 days to Oct 21, 2026
Buys
0
Sells
31
Net $
-$6.0M
Unique insiders
11
DateInsiderRoleTypeSharesValue
Sep 30, 26Cohen Raymond WDirectorSELL3.3K$98K
Sep 21, 26Kwo ElizabethDirectorSELL4.0K$97K
Sep 8, 26Schwartz Jeffrey LawrenceDirectorSELL3.9K$98K
Sep 8, 26Reilly Kevin CDirectorSELL2.9K$74K
Sep 8, 26Ladone Mary KayDirectorSELL3.9K$98K
Sep 8, 26Hanley ConorDirectorSELL5.7K$144K
Aug 17, 26Webster Brian DanielSee RemarksSELL15.0K$412K
Aug 7, 26Mahboob VaseemChief Financial OfficerSELL25.8K$667K
Aug 7, 26Mahboob VaseemChief Financial OfficerSELL500$13K
Aug 4, 26Webster Brian DanielSee RemarksSELL48.6K$1.2M

SEC Form 4 filings as of Oct 21, 2026

See cluster-buy signals across all tickers →

KMTS price chart

Powered by TradingView

What does KESTRA MEDICAL TECHNOLOGIES, LTD. do?

Kestra Medical Technologies Inc. is a company specializing in the development and production of innovative medical devices. The core function of Kestra is to design wearable medical technologies aimed at improving patient outcomes in critical health areas. Primarily, the company engages in creating devices that focus on cardiac care, providing solutions that monitor, diagnose, and assist in the management of heart conditions. Kestra Medical Technologies addresses significant needs within the healthcare sector, particularly impacting the cardiology field by offering devices that enhance both the quality and efficiency of patient care. As a player in the medical technology industry, Kestra is positioned to influence patient health management trends and contribute to the advancement of medical device technologies. Its products serve as critical tools for healthcare providers aiming to offer cutting-edge care solutions.

CEO
Mr. Brian Webster
Employees
330
Ask about KMTSAI research agent